Educational use only. Check doses against the product monograph and local protocols.

GLP-1 receptor agonists

in review 4 min read Updated 2026-11-19
GLP-1 receptor agonists

Nutrient-stimulated hormone agonists (GLP-1 RAs and the dual GIP/GLP-1 RA tirzepatide) delivering potent A1C reduction, substantial weight loss, negligible intrinsic hypoglycaemia, and proven ASCVD, CKD, HFpEF, OSA, and MASH benefits (agent-specific). Contraindicated in medullary thyroid carcinoma / MEN2 and pregnancy.

medullary thyroid carcinoma and MEN2

Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2 (rodent C-cell tumour boxed warning).


mechanism

Activate GLP-1 receptors (and GIP receptors for tirzepatide) → glucose-dependent insulin secretion, suppressed postprandial glucagon, slowed gastric emptying, and central hypothalamic satiety signalling.


comparison and dosing

Titrate slowly every 4 weeks to limit nausea/vomiting. No dose adjustment down to eGFR 15 mL/min/1.73 m² (limited data <15 or on dialysis).

agentroute & scheduleT2DM max doseobesity doseproven organ-outcome benefits
semaglutide (Ozempic / Wegovy / Rybelsus)SC weekly (or PO daily)2 mg SC weekly (14 mg PO daily)2.4 mg SC weeklyMACE in T2DM (SC) and non-diabetic ASCVD + BMI ≥27 (2.4 mg); CKD progression & CV death in T2DM (1 mg); HFpEF symptoms/events (2.4 mg); MASH resolution & fibrosis; knee OA pain
tirzepatide (Mounjaro / Zepbound)SC weekly (dual GIP/GLP-1)15 mg weekly5, 10, or 15 mg weeklylargest A1C and weight loss (~15–21%); HFpEF CV death/worsening HF (15 mg); moderate–severe OSA (10–15 mg); MASH; dedicated T2DM CVOT/CKD trials pending
liraglutide (Victoza / Saxenda)SC daily1.8 mg daily3 mg dailyMACE & CV mortality in T2DM; prediabetes progression; OSA (3 mg). Avoid in acute HFrEF (↑ HF events)
dulaglutide (Trulicity)SC weekly4.5 mg weeklyT2DM onlyMACE (primary + secondary CV prevention in T2DM), ↓ stroke
  • Avoid exenatide and lixisenatide when cardiorenal protection is the goal — neutral for MACE. Oral semaglutide lacks proven cardiorenal superiority in Diabetes Canada 2024 (take fasting with ≤120 mL water, wait ≥30 min before food/meds).

key points

  • Do not combine with DPP-4 inhibitors (redundant mechanism; stop DPP-4i when starting a GLP-1 RA or tirzepatide).
  • Concomitant sulfonylurea or insulin: intrinsic hypoglycaemia risk is negligible, so reduce sulfonylurea or insulin doses when adding a GLP-1 RA to avoid lows.
  • Weight regain on stopping: obesity trials consistently show regain of weight and loss of cardiometabolic benefit after discontinuation → treat as long-term chronic therapy (obesity).
  • Diabetic retinopathy: rapid A1C lowering (notably SC semaglutide) can transiently worsen pre-existing proliferative retinopathy → ensure baseline dilated eye exam and close monitoring in high-risk patients.
  • Pregnancy & contraception: avoid in pregnancy; counsel on reliable contraception and stop before planned conception. Tirzepatide reduces oral contraceptive absorption via delayed gastric emptying — use non-oral or backup contraception for 4 weeks after initiation and each dose escalation (ADA 2026).
  • Do not use compounded products: Obesity Canada 2025 and ADA 2026 recommend against non-approved compounded formulations.
  • Ontario: ODB covers SC semaglutide (Ozempic) under LU 665–667 and oral semaglutide (Rybelsus) under LU 662–664 / 738–740 for T2DM inadequately controlled on max tolerated metformin; Wegovy, Saxenda, and tirzepatide are not ODB-covered.

adverse effects

  • GI (most common, dose-dependent, improves with slow titration): nausea, vomiting, diarrhoea, constipation, dyspepsia, delayed gastric emptying (aspiration/ileus caution; avoid in severe gastroparesis).
  • Gallbladder disease: cholelithiasis and cholecystitis (rapid weight loss + reduced gallbladder motility).
  • Pancreatitis: caution with prior pancreatitis; discontinue if suspected (large RCTs show no clear excess risk).
  • Retinopathy worsening: associated with rapid A1C drop in established retinopathy.
  • MTC / MEN2: contraindicated (boxed warning).

evidence

  • SUSTAIN-6 / SELECT / FLOW / STEP-HFpEF: SC semaglutide lowers MACE in T2DM and non-diabetic ASCVD + obesity, reduces kidney failure and CV death in T2DM-CKD, and improves HFpEF symptoms/events (Obesity Canada 2025, ADA 2026).
  • SURMOUNT-1 / SUMMIT / SURMOUNT-OSA: tirzepatide achieves 15–21% weight loss, cuts HFpEF CV death/worsening HF events, and reduces OSA apnoea-hypopnoea index (Obesity Canada 2025).
  • LEADER / REWIND: liraglutide (CV death + MACE) and dulaglutide (MACE + stroke) establish cardiorenal protection in T2DM (Diabetes Canada 2024).

Prepared 2026-11-19. Not yet verified — check every number against the sources.

Key references

+3 more sources

Suggest a correction GLP-1 receptor agonists